PHILADELPHIA, PA / ACCESSWIRE / Olfactory Biosciences Corp (OLFC) the maker of NOXO Autism Balm(TM), is pleased to announce today that they are receiving positive proof of product claims / testimonials from families, doctors, therapists and caregivers involved with Autism Spectrum Disorders. And in addition, one of the top advances in Autism Spectrum Diseases.
More importantly, of the major advances in autism, NOXO Autism Balm(TM) is the only one now available on Amazon.
NOXO is Non-Invasive, Normalizes Brain Patterns and Provides Tranquility.
Amazon has received feedback of 4.2 stars of 5 with a 97% rating.
NOXO Autism Balm(TM) was invented by the company's Research Director, Dr. V Ruth Pinney using NOBEL Prize Winning in Medicine, in 2004, (Richard Axel and Linda Buck), to 'tone down' the overwhelming perceptions by those with Autism. www.noxoinfo.com/autism.html
Autism 2013 Highlights of the year also included:
1. Whole Genome Sequencing Advances Autism Diagnosis and Personalized Care
2. Researchers Identify Earliest Known Sign of Autism; Potential Window for Very Early Intervention
3. Strong Evidence that Prenatal Folic Acid Can Reduce Autism Risk
4. Gene Study of Neurodevelopmental Disorders Finds Overlap between Autism and Major Mental-Health Conditions
5. New Tools Enable Investigators to Track Activity of Autism-linked Genes
6. "Optimal Outcomes" Rare but Real in Autism
7. Beyond Autism Genes: Epigenetic Differences in Identical Twins
8. Autism, Long Genes and DNA Detangles
9. 'Good' Bacteria Ease Autism-like Behaviors in Mouse Model
10. Large Study Supports GI Link to Problem Behaviors in Kids with Autism
Olfactory Biosciences Director of Research, Dr. V. Ruth Pinney states that what makes NOXO's Autism Balm(TM) unique is that it targets sensitivities naturally, changing the child's perception to sensory inputs in a direct, safe way!"
You can get more information or buy NOXO Autism balm(TM) at: www.noxoinfo.com/autism.html NOXO is Amazon Guaranteed
About Olfactory Biosciences Corp
Olfactory Biosciences Corp.'s NOXO division is focused to develop a variety of products targeting Olfactory Receptors in the nose for the desired effect. These alternative medicine wellness products can modify behavior or provide relief to common behavior challenges such as anxiety, or weight control, as examples.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements by the Company, statements regarding the NOXO product line, optimism related to the business, expanding ales and other statements in this press release are forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates and projections about the Company's business. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many factors including continued market acceptance of the Company's products or the need to raise additional capital. In addition, actual results could vary materially based on changes or slower growth in the indoor garden market; the potential inability to realize expected benefits and synergies; domestic and international business and economic conditions; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors listed from time to time in the Company's Securities and Exchange Commission(SEC) filings under "risk
factors" and elsewhere. The forward-looking statements contained in this press release speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.
Olfactory Biosciences Corp.
333 E. Lancaster Ave.
Wynnewood, PA 19096, USA
Source: Olfactory Biosciences Corp
- Disease & Medical Conditions
- Autism Spectrum Disorders